Pre-made Otelixizumab benchmark antibody ( Whole mAb, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Otelixizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Otelixizumab, also known as TRX4, is a monoclonal antibody,[1] which is being developed for the treatment of type 1 diabetes and other autoimmune diseases. The antibody is being developed by Tolerx, Inc. in collaboration with GlaxoSmithKline and is being manufactured by Abbott Laboratories.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-414-1mg	1mg	3090
GMP-Bios-ab-414-10mg	10mg	Inquiry
GMP-Bios-ab-414-100mg	100mg	Inquiry
GMP-Bios-ab-414-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Otelixizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody
INN Name	Otelixizumab
Target	CD3E
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2007
Year Recommended	2008
Companies	BTG;GlaxoSmithKline;Tolerx
Conditions Approved	na
Conditions Active	Type 1 diabetes mellitus
Conditions Discontinued	Graves ophthalmopathy;Multiple sclerosis;Myasthenia gravis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis
Development Tech	na